Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

  • STATUS
    Recruiting
  • End date
    Feb 15, 2025
  • participants needed
    31
  • sponsor
    Mayo Clinic
Send
Updated on 16 October 2022
See if I qualify

Summary

This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread to other places in the body. PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Description

PRIMARY OBJECTIVE:

I. To estimate the overall tumor response rate (overall response rate [ORR], that is, complete response [CR] + partial response [PR], according to Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] of PLX038 in the setting of metastatic platinum resistant high grade serous ovarian cancer.

SECONDARY OBJECTIVES:

I. To estimate the progression-free survival and overall survival of treatment with PLX038.

II. To describe and assess tolerability of PLX038. III. Measure PLX038 induced tumor TOP1-deoxyribonucleic acid (DNA) covalent complexes (TOP1cc) in pretreatment and Cycle 1 Day 8 biopsies to confirm persistent stabilization of TOP1cc and evaluate association with tumor response rate.

CORRELATIVE RESEARCH:

I. Measure TOP1cc in circulating tumor cells and evaluate association with TOP1cc in tumor tissue and tumor response rate.

II. Assess homologous repair status and association with tumor response. III. Assess expression of SN-38 transports by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and association with tumor response.

OUTLINE

Patients receive PLX038 intravenously (IV) over 1 hour on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and every 6 months for up to 5 years.

Details
Condition Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Treatment biopsy, Pegylated SN-38 Conjugate PLX038
Clinical Study IdentifierNCT05465941
SponsorMayo Clinic
Last Modified on16 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age >= 18 years NOTE: Because no dosing or adverse event data are currently available on the use of PLX038 in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
Histological confirmed high grade serous ovarian cancer consistent with ovarian, fallopian tube, or primary peritoneal carcinoma (NOTE: Any of these diseases are referred to in this protocol as "ovarian cancer")
Recurrent high grade serous ovarian cancer that was initially platinum sensitive (i.e., had at least one platinum-free interval of at least 6 months before progression) is now platinum resistant
No more than one prior line of therapy for platinum resistant disease. NOTE: Prior poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy is allowed
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Disease that is amenable to two biopsies
Life expectancy greater >= 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
Hemoglobin >= 8.0 g/dL (obtained =< 28 days prior to registration)
Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 28 days prior to registration)
Platelet count >= 100,000/mm^3 (obtained =< 28 days prior to registration)
Total bilirubin >= 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to registration)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement) (obtained =< 28 days prior to registration)
Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to registration)
Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Provide written informed consent
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willingness to provide mandatory blood specimens for correlative research
Willingness to provide mandatory tissue specimens for correlative research

Exclusion Criteria

Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects
Pregnant persons
Nursing persons
Persons of childbearing potential who are unwilling to employ adequate contraception
Histology other than high grade serous carcinoma
Prior treatment restrictions
Chemotherapy =< 4 weeks prior to registration
Immunotherapy =< 4 weeks prior to registration
Radiotherapy =< 4 weeks prior to registration
Any other investigational therapy =< 4 weeks prior to registration
History of prior or concurrent malignancy =< 2 years prior to registration
Exceptions: If natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
Uncontrolled intercurrent illness including, but not limited to
Myocardial infarction within 6 months of study entry
New York Heart Association (NYHA) class III or IV heart failure
Uncontrolled dysrhythmias or poorly controlled angina
History of serious ventricular arrhythmia (ventricular tachycardia [VT] or ventricular fibrillation [VF]) and/or factors that predispose to arrhythmia (e.g., heart failure, hypokalemia, family history of long QT syndrome)
Known history or current symptoms of cardiac disease, or history of treatment with
cardiotoxic agents, Exception: Patients should have a clinical risk assessment
of cardiac function using the New York Heart Association functional
classification. To be eligible for this trial, patients should be class 2B or
better
Known human immunodeficiency virus (HIV) Exception: Patients on effective anti-retroviral therapy with undetectable viral load =< 6 months prior to registration are eligible for this trial
Known hepatitis
Exception: For patients with evidence of chronic hepatitis B virus infection the HepB viral load must be undetectable on suppressive therapy, if indicated, to be eligible
Exception: Patients with a history of hepatitis C virus infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
Receiving any other investigational agent
History of clinically significant gastrointestinal bleeding, colitis, or gastrointestinal perforation
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimen
Requirement for anticoagulation treatment that increases international normalized ratio (INR) or activated partial thromboplastin time (APTT) above the normal range (Exceptions: low dose deep vein thrombosis (DVT) or line prophylaxis allowed
Known central nervous system (CNS) disease Exception: Patients with treated brain metastases are eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the 1st cycle of therapy
Known Gilbert's syndrome or homozygous for the UGT1A128 variant allele or other relevant alleles with severely reduced UGT1A1 activity
Patients who require treatment with UGT1A1 inhibitors during the planned period of investigational treatment with PLX038
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note